Polypill-Based Therapy: A Promising Therapeutic Strategy.
作者信息
Luo Fei, Guo Yuan, Peng Ran, Ruan Guiyun, Li Xiangping
机构信息
Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
出版信息
Heart Lung Circ. 2017 May;26(5):423-424. doi: 10.1016/j.hlc.2017.02.004. Epub 2017 Mar 6.
PMID:28320637
Abstract
摘要
相似文献
1
Polypill-Based Therapy: A Promising Therapeutic Strategy.基于复方制剂的治疗：一种有前景的治疗策略。
Heart Lung Circ. 2017 May;26(5):423-424. doi: 10.1016/j.hlc.2017.02.004. Epub 2017 Mar 6.
2
Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.最大化预防心血管疾病的治疗范围：复方制剂的作用
Mt Sinai J Med. 2012 Nov-Dec;79(6):683-8. doi: 10.1002/msj.21355.
3
What happened to the polypill?复方制剂怎么了？
BMJ. 2008 Sep 26;337:a1822. doi: 10.1136/bmj.a1822.
4
Reflections on the regulation of the Polypill.关于复方药丸监管的思考。
Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):94-5. doi: 10.1038/ncpcardio1416. Epub 2008 Dec 2.
5
The polypill concept.多效药丸概念。
Postgrad Med J. 2010 May;86(1015):257-60. doi: 10.1136/hrt.2009.186429.
6
Time to implement the polypill approach.是时候采用复方制剂方法了。
N Z Med J. 2009 Jun 5;122(1296):88-9.
7
Why is there more heat than light concerning the polypill?关于复方制剂，为什么热度高于关注度？
BMJ. 2008 Oct 20;337:a2162. doi: 10.1136/bmj.a2162.
8
Has the polypill finally proven its worth?复方制剂最终证明了其价值吗？
Drug Ther Bull. 2019 Dec;57(12):178. doi: 10.1136/dtb.2019.000027.
9
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.福斯特-西班牙国家心血管研究中心-费雷尔心血管复方制剂：一种用于心血管疾病二级预防的复方制剂
Int J Cardiol. 2015 Dec;201 Suppl 1:S15-22. doi: 10.1016/S0167-5273(15)31028-7.
10
FDA, advisers mull "polypill" for patients with cardiovascular disease.美国食品药品监督管理局（FDA）的顾问们在考虑为心血管疾病患者提供“复方药丸”。
Am J Health Syst Pharm. 2014 Nov 15;71(22):1918, 1920. doi: 10.2146/news140077.
Zotero 插件